| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:868.)
© 2006 American Heart Association, Inc.
Original Articles |
From the Veterans Administration Medical Center (P.N., V.P.), Washington, DC; Glostrup University Hospital (K.W.), Glostrup, Denmark; Weill Medical College of Cornell University (K.W., R.B.D.), New York, NY; Haukeland University Hospital (E.G.), Bergen, Norway; Skellefteå Hospital (K.B.), Umeå, Sweden; Helsinki University Central Hospital (M.S.N.), Helsinki, Finland; Sahlgrenska/Östra Hospital (B.D.), Göteborg, Sweden; and Ullevaal University Hospital (A.H.), Oslo, Norway.
Correspondence to Puneet Narayan, Division of Cardiology Research, Room GE 240, Veterans Administration Medical Center, 50 Irving St NW, Washington, DC 20422. E-mail pnarayan{at}dnamail.com
| Abstract |
|---|
|
|
|---|
Key Words: hypertension hemoglobin echocardiography
| Introduction |
|---|
|
|
|---|
A potential causal role of hematocrit in hypertension is supported by changes in blood pressure seen with treatment of anemia in many disease states with a rise in blood pressure levels in response to treatment of anemia with erythropoietin in chronically ill patients.13 However, there are conflicting results; one study found correlation between whole blood viscosity and LV mass,14 whereas another found that whole blood viscosity was related to LV wall thickness more than to LV mass.15 To our knowledge, there has been no previous investigation of the relation between systemic hemoglobin delivery and LV structure and function.
The present study was undertaken to investigate the relations of hemoglobin level and the product of hemoglobin concentration multiplied by cardiac output as an index of oxygen delivery, with LV size and function in a large population of hypertensive patients with electrocardiographic LV hypertrophy enrolled in the Losartan Intervention For End point reduction in hypertension (LIFE) echocardiography substudy.
| Methods |
|---|
|
|
|---|
2440 mVxms) or Sokolow-Lyon voltage criteria (SV1+RV5/RV6 >38 mm).1618 After signing ethics committeeapproved informed consent, patients were taken off all antihypertensive medications and entered into a 2-week, single-blind placebo phase, after which baseline measurements were obtained. These included laboratory blood samples for hemoglobin and serum chemistry, and a 12-lead ECG.
A subset of
10% of the total LIFE patient population participated in the LIFE echocardiographic study and had M-mode, 2D, and Doppler echocardiograms performed as described previously.1921 Doppler echocardiographic recordings were made with the patients in the left decubitus position, following previously published and standardized protocols.19 LV chamber dimensions and wall thicknesses were measured following the American Society of Echocardiography standards.22,23 Relative wall thickness was calculated at end diastole as posterior wall thickness (PWT)/internal radius, the LV ejection fraction by the Teichholz method, and LV mass using an autopsy-validated formula.2426 LV hypertrophy was considered present if LV mass/body surface area was >116 g/m2 in men and 104 g/m2 in women.27 Midwall fractional shortening (FS) was calculated from LV linear dimensions using a previously validated formula.28
Stroke volume was calculated by the invasively validated aortic annular leading edge method as (aortic annular cross-sectional area)x(Doppler time velocity integral of aortic annular flow)29 and used to calculate cardiac output and total peripheral resistance. Hemoglobin delivery to peripheral tissues was calculated by multiplying the cardiac output in liters per minute by the hemoglobin concentration in grams per deciliter. The oxygen-delivery capacity per minute associated with the observed hemoglobin delivery was estimated by multiplying the hemoglobin delivery by the average oxygen extracted from each gram of hemoglobin in normal adults. Each gram of hemoglobin binds 1.34 mL of oxygen when 100% saturated. The hemoglobin in arterial blood is, on average, 99% saturated at rest, and in mixed venous blood at rest, the hemoglobin is
75% saturated. Thus, at rest, the tissues remove
0.344 mL of oxygen per gram of hemoglobin.30
Statistical Analysis
Data were analyzed using SPSS 12.0.1 statistical software (SPSS, Inc). Results are mean±SD or 95% confidence interval, when appropriate, and frequencies are expressed as percentages. Differences in continuous variables between 2 groups were assessed by Student t test for parametric data, with log transformation when needed to satisfy the assumption of normality and
2 analysis for categorical data. Independent correlates of continuous measures of LV geometry were identified by multiple linear regression analysis using an enter procedure with assessment of colinearity diagnostics. Two-tailed P<0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
8% higher in men than women (Table 2). There was no gender difference in mean glucose level, but men had higher plasma creatinine levels and exhibited trends toward greater albuminuria compared with women. Men also had lower mean values than women for total and especially for high-density lipoprotein (HDL) cholesterol concentration.
|
|
Echocardiographic Findings
Echocardiographic variables are described in Table 3. As expected, LV wall thicknesses, chamber size, and mass, both in absolute terms and indexed for body surface area, were higher in men; there was no gender difference in LV relative wall thickness. Stroke volume was larger in men than women, but there was no gender difference in cardiac output because of the higher heart rate in women. Peripheral resistance index was higher and cardiac index lower in male than female LIFE patients. Measures of LV systolic chamber and midwall function were higher in women than men, as were the peak velocities of blood flow across the mitral valve in early diastole and with atrial systole.
|
Relations of Hemoglobin to Clinical Characteristics
Among women, hemoglobin concentration had a significant positive relation with total cholesterol level and a negative relation with serum creatinine (Table 4) but was not significantly related to age, systolic or diastolic blood pressure, age, body mass index, log urine albumin/creatinine, serum glucose, or HDL cholesterol levels (all P>0.20). Among men, hemoglobin concentration had significant positive relations with diastolic blood pressure, total cholesterol level (both P<0.001), and body mass index (P=0.03) and negative relations with plasma creatinine and age (P<0.001; Table 4), but not with log urine albumin/creatinine, serum glucose, or systolic blood pressure (all P>0.10).
|
Relations of Hemoglobin to Echocardiographic Findings
Among women, there was a weak negative relation of hemoglobin level with LV internal dimension (P<0.05) but not with LV wall thicknesses, mass, or relative wall thickness. Similarly, there was no significant relation between hemoglobin level and stroke volume, cardiac output, peripheral resistance, or measures of LV systolic chamber or midwall function (Table 4).
Among men, the hemoglobin level was negatively related to stroke volume (r=0.13; P=0.005) but not other measures of LV geometry or function or of systemic hemodynamics, whereas hemoglobin delivery was positively related to LV internal dimension (r=0.23; P<0.001) and LV mass (r=0.17; P<0.001) and negatively related to relative wall thickness and LV midwall shortening (both r=0.14; P=0.004).
Relations of Hemoglobin Delivery to Clinical and Echocardiographic Findings
Among women, hemoglobin delivery was positively related to systolic blood pressure and negatively to serum creatinine and HDL cholesterol levels among clinical variables (Table 5). There were also positive relations between hemoglobin delivery and LV internal dimension, septal and PWTs, LV mass, endocardial and midwall FS, and cardiac index and a negative relation with total peripheral resistance index. Among measures of LV diastolic filling, hemoglobin delivery was positively related to the peak A wave velocity and negatively related to the E/A ratio, deceleration time of early diastolic LV inflow, and the isovolumic relaxation time.
|
Among men, hemoglobin delivery was positively related to diastolic blood pressure, body mass index, and glucose level and negatively to age and plasma creatinine level but was statistically unrelated to systolic blood pressure, total cholesterol, log urine albumin/creatinine, or HDL cholesterol level (Table 5). There were also positive relations of hemoglobin delivery with LV internal dimension, LV mass, and cardiac index, and negative relations between hemoglobin delivery and LV midwall shortening and relative wall thickness, as well as total peripheral resistance index. Among indices of LV diastolic filling, the peak A wave velocity was positively and the E/A ratio negatively related to hemoglobin delivery in men, without relations with other diastolic filling variables.
Multivariate Analyses of Hemoglobin
A series of regression models were developed that included clinical variables associated with hemoglobin level or hemoglobin delivery in either gender, including diastolic blood pressure, total cholesterol, body mass index, and age as covariates based on their univariate associations with hemoglobin level. Among women, hemoglobin level had independent negative relations to mitral valve E velocity (ß=0.188; P=0.001) and A velocity (ß=0.132; P=0.027) but was not independently related to septal or PWT, LV internal diameter, LV mass, relative wall thickness, FS, midwall shortening, mitral valve E/A ratio, deceleration time, or isovolumic relaxation time. Among men, hemoglobin level was not independently related to any of the LV geometric or functional variables under consideration.
Multivariate Analyses of Hemoglobin Delivery
Hemoglobin delivery in women had positive relations, independent of the same covariates, with LV FS (ß=0.229), midwall shortening (ß=0.223; both P<0.001), LV mass (ß=0.159; P=0.008), mitral valve A velocity (ß=0.137; P=0.021), and LV internal dimension (ß=0.121; P=0.037) and was negatively related to the mitral valve deceleration time (ß=0.203; P<0.001) and isovolumic relaxation time (ß=0.130; P=0.028). No independent relation existed between hemoglobin delivery in women and septal or PWT, relative wall thickness, or mitral valve E velocity or E/A ratio.
Among men, hemoglobin delivery had positive independent relations to the mitral valve A velocity (ß=0.186; P<0.001), LV internal dimension (ß=0.188; P<0.001), midwall shortening (ß=0.146; P=0.001), and LV mass (ß=0.115; P=0.016) and negative relations to the mitral valve E/A ratio (ß=0.144; P=0.002) and relative wall thickness (ß=0.135; P=0.003) but was not related to septal or PWT, FS, E velocity, deceleration time, or the isovolumic relaxation time.
| Discussion |
|---|
|
|
|---|
The association of higher hemoglobin delivery with larger LV chamber size and higher LV mass observed in both women and men in the present study is primarily because of the strong contribution of higher cardiac output to greater hemoglobin delivery. These findings help draw together several lines of evidence obtained in previous studies. First, a strong positive relation between Doppler stroke volume and LV mass, independent of the level of blood pressure and other covariates, has been documented in a large, population-based sample.32 Second, higher cardiac output has been demonstrated in both mildly hypertensive patients19 and LIFE participants with more elevated blood pressure20 compared with age- and sex-matched normotensive adults. Finally, higher fat-free mass, a major determinant of greater tissue oxygen demand, has been documented in hypertensive members of a population-based sample33 and related to higher cardiac output in that setting. Although fat-free mass was not measured in the LIFE study, it is attractive to speculate that greater tissue mass would have been present in patients with higher hemoglobin delivery and greater LV chamber size and mass in the population of this study.
Another novel and potentially important finding of the present study is that of negative relations between indices of impaired LV diastolic relaxation and hemoglobin delivery. Although Doppler features of abnormal LV filling, including reduced E/A ratio, and prolonged deceleration and isovolumic relaxation times, are detected in many hypertensive patients, the clinical significance of these findings is often unclear. The present observations suggest that impaired LV diastolic filling might, by reducing oxygen delivery, lead to greater fatigue and reduced exercise tolerance. Because these were not measured in the LIFE study, further research will be needed to address this possibility.
These observations may be relevant to a spectrum of medical conditions. It is common for patients with renal disease and with anemia from diverse etiologies to be treated to improve hemoglobin levels. Whereas such interventions improve hemoglobin and may increase exercise tolerance, it is a clinical observation that blood pressure rises. Our study suggests that enhancement of hemoglobin delivery to peripheral tissues may contribute to this rise in blood pressure by increasing blood viscosity because of higher hemoglobin, as well as by a direct vasoconstrictive effect of administered erythropoietin.34 Further studies are needed to identify the optimal hemoglobin level and capacity to deliver oxygen for sound cardiovascular health with optimum cardiovascular outcomes.
Perspectives
Results of this study reveal that greater hemoglobin delivery is associated with more abnormal parameters of LV structure but also less abnormal diastolic function in patients with hypertension and LV hypertrophy. Most of the echocardiographic parameters did not, per se, correlate with the hemoglobin level; thus, it is important to look at both viscosity as determined by hematocrit level and the level of tissue oxygenation, as reflected by hemoglobin delivery, when determining the possible outcomes of therapies aiming to improve hemoglobin levels and oxygenation in patients with anemia of chronic disease.
| Acknowledgments |
|---|
Received July 20, 2005; first decision August 8, 2005; accepted February 16, 2006.
| References |
|---|
|
|
|---|
2. Fowkes FG, Lowe GD, Rumley A, Lennie SE, Smith FB, Donnan PT. The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J. 1993; 14: 597601.
3. Klein W, Eber B, Dusleag J, Gasser R, Fruhwald FM, Schumacher M, Zweiker R, Stoschitzky K. Hypertension and hemorheology. Wien Med Wochenschr. 1995; 145: 355357.[Medline] [Order article via Infotrieve]
4. Simpson LO. Blood pressure and blood viscosity. N Z Med J. 1988; 101: 581.[Medline] [Order article via Infotrieve]
5. London M. The role of blood rheology in regulating blood pressure. Clin Hemorheol Microcirc. 1997; 17: 93106.[Medline] [Order article via Infotrieve]
6. Koenig W, Sund M, Ernst E, Matrai A, Keil U, Rosenthal J. Is increased plasma viscosity a risk factor for high blood pressure? Angiology. 1989; 40: 153163.[Medline] [Order article via Infotrieve]
7. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Role of fibrinogen and concentration. Am J Med. 1981; 70: 11951202.[CrossRef][Medline] [Order article via Infotrieve]
8. Rim SJ, Leong-Poi H, Lindner JR, Wei K, Fisher NG, Kaul S. Decrease in coronary blood flow reserve during hyperlipidemia is secondary to an increase in blood viscosity. Circulation. 2001; 104: 27042709.
9. Gobel BO, Schulte-Gobel A, Weisser B, Glanzer K, Vetter H, Dusing R. Arterial blood pressure. Correlation with erythrocyte count, hematocrit, and hemoglobin concentration. Am J Hypertens. 1991; 4: 1419.[Medline] [Order article via Infotrieve]
10. Fossum E, Hoieggen A, Moan A, Nordby G, Velund TL, Kjeldsen SE. Whole blood viscosity, blood pressure and cardiovascular risk factors in healthy blood donors. Blood Press. 1997; 6: 161165.[Medline] [Order article via Infotrieve]
11. Folkow B. The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med. 1978; 4 (suppl): 3s22s.
12. Ruiz L, Penaloza D. Altitude and hypertension. Mayo Clin Proc. 1977; 52: 442445.[Medline] [Order article via Infotrieve]
13. Sunder-Plassmann G, Horl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis. 2001; 38 (4 Suppl 1): S20S25.[Medline] [Order article via Infotrieve]
14. Devereux RB, Drayer JI, Chien S, Pickering TG, Letcher RL, DeYoung JL, Sealey JE, Laragh JH. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol. 1984; 54: 592595.[CrossRef][Medline] [Order article via Infotrieve]
15. de Simone G, Devereux RB, Roman MJ, Ganau A, Chien S, Alderman MH, Atlas S, Laragh JH. Gender differences in left ventricular anatomy, blood viscosity and volume regulatory hormones in normal adults. Am J Cardiol. 1991; 68: 17041708.[CrossRef][Medline] [Order article via Infotrieve]
16. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention for Endpoint Reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997; 10: 705713.[CrossRef][Medline] [Order article via Infotrieve]
17. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998; 32: 989997.
18. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 9951003.[CrossRef][Medline] [Order article via Infotrieve]
19. Devereux RB, Bella J, Boman K, Gerdts E, Nieminen MS, Rokkedal J, Papademetriou V, Wachtell K, Wright J, Paranicas M, Okin PM, Roman MJ, Smith G, Dahlöf B. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press. 2001; 10: 7482.[CrossRef][Medline] [Order article via Infotrieve]
20. Bella JN, Wachtell K, Palmieri V, Liebson PR, Gerdts E, Ylitalo A, Koren MJ, Pedersen OL, Rokkedal J, Dahlöf B, Roman MJ, Devereux RB. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention for Endpoint Reduction in Hypertension Study. J Hypertens. 2001; 19: 127134.[CrossRef][Medline] [Order article via Infotrieve]
21. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Dahlöf B. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction in Hypertension. J Hypertens. 2000; 18: 11291138.[CrossRef][Medline] [Order article via Infotrieve]
22. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 10721083.
23. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik J. Recommendations for quantitation of the left ventricle by 2-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989; 2: 358367.[Medline] [Order article via Infotrieve]
24. Gutgesell HP, Paquet M, Duff DF, McNamara DG. Evaluation of left ventricular size and function by echocardiography. Results in normal children. Circulation. 1977; 56: 457462.
25. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976; 37: 711.[CrossRef][Medline] [Order article via Infotrieve]
26. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57: 450458.[CrossRef][Medline] [Order article via Infotrieve]
27. Devereux RB, Dahlöf B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol. 1996; 78: 6165.[Medline] [Order article via Infotrieve]
28. de Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994; 23: 14441451.(Correction 1994;24:844.)[Abstract]
29. Dubin J, Wallerson DC, Cody RJ, Devereux RB. Comparative accuracy of Doppler echocardiographic methods for clinical stroke volume determination. Am Heart J. 1990; 120: 116123.[CrossRef][Medline] [Order article via Infotrieve]
30. Ganong WF. Review of Medical Physiology. Tenth Edition. New York, NY: Lange Medical Publications; 1981: 521.
31. Giannattasio C, Piperno A, Failla M, Vergani A, Mancia G. Effects of hematocrit changes on flow-mediated and metabolic vasodilation in humans. Hypertension. 2002; 40: 7477.
32. Devereux RB, Roman MJ, de Simone G, OGrady MJ, Paranicas M, Yeh JL, Fabsitz RR, Howard BV. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation. 1997; 96: 14161423.
33. Devereux RB, Chinali M, Liu JE, Roman MJ, Best LG, Galloway JM, Lee ET, de Simone G, Howard BV. Association of fat-free mass with hypertension: The Strong Heart Study. Circulation. 2003; 108 (Suppl-IV): IV-631.
34. Sasagawa I, Nakada T, Hashimoto T, Kubota Y, Suzuki H, Sawamura T. Change in haemoglobin concentration, haematocrit and vasoactive hormones in haemodialysis patients with erythropoietin-associated hypertension. Int Urol Nephrol. 1994; 26: 237243.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
D. J. Weaver Jr., T. R. Kimball, T. Knilans, W. Mays, S. K. Knecht, Y. M. Gerdes, S. Witt, B. J. Glascock, J. Kartal, P. Khoury, et al. Decreased Maximal Aerobic Capacity in Pediatric Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2008; 19(3): 624 - 630. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |